Cure8 research brief
This meta-analysis examined whether IL-23 inhibitors work differently depending on ulcerative colitis extent; results may inform expectations about induction and maintenance response across disease patterns.
Clinicians treating ulcerative colitis, IBD researchers, and adult patients considering IL-23 pathway therapies.
This systematic review and meta-analysis pooled randomized placebo-controlled trials of IL-23 pathway inhibitors in ulcerative colitis to compare treatment effects by baseline disease extent (limited versus extensive).
The authors found that IL-23 inhibitors increased clinical remission during induction for both limited and extensive disease with no significant difference between extents. During maintenance therapy, therapies were effective for both groups but showed a larger relative effect in patients with extensive disease.
Summary grounded in the article abstract (systematic review/meta-analysis). The interaction finding applies to relative treatment effects during maintenance and should be interpreted alongside full trial details and clinical context.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
The review suggests baseline corticosteroid use may change how well some advanced UC therapies work, especially IL-23 inhibitors and S1P modulators, which could affect treatment choices and trial reporting.
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
